Edgewise Boosts R&D Spending in Q4 as Drug Milestones Approach

Biopharmaceutical company focused on muscle diseases sees increased expenses amid clinical development progress.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Edgewise Therapeutics Inc., a Boulder-based biopharmaceutical company developing therapies for muscle diseases, reported increased research and development (R&D) and administrative spending in the fourth quarter of 2025 as the company advanced clinical trials for several drug candidates in its pipeline.

Why it matters

Edgewise's increased investment in R&D signals the company's commitment to advancing its pipeline of potential treatments for serious muscle disorders, which often lack adequate treatment options. The company's progress could lead to new therapeutic options for patients living with these debilitating conditions.

The details

Edgewise's R&D expenses totaled $43.6 million in Q4 2025, up from $37.5 million in the previous quarter. General and administrative spending also rose, from $9.4 million to $12.4 million over the same period. The company's net loss for the quarter was $50.2 million, up from $40.7 million in Q3 2025.

  • Edgewise reported financial results for the fourth quarter of the 2025 fiscal year.
  • The company's R&D and administrative spending increased from the previous quarter.

The players

Edgewise Therapeutics Inc.

A Boulder-based biopharmaceutical company that develops therapies for muscle diseases.

Kevin Koch

The CEO of Edgewise Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“Following strong execution in 2025, we have entered a transformative year, with development milestones and trial results expected for several of Edgewise's drug candidates. With multiple near-term catalysts and a high-performing team, we are closer than ever to delivering transformative medicines for patients living with serious conditions that still lack adequate treatment options and represent significant unmet medical needs.”

— Kevin Koch, CEO (Edgewise Therapeutics)

What’s next

Edgewise expects to reach several development milestones and report trial results for its drug candidates in the coming year, which could lead to new treatment options for patients with muscle diseases.

The takeaway

Edgewise's increased investment in research and development signals the company's commitment to advancing its pipeline of potential therapies for serious muscle disorders, which often lack adequate treatment options. The company's progress could lead to new therapeutic options for patients living with these debilitating conditions.